Expression of Versican and Its Related Molecules in Patient with Multiple Myeloma and Its Clinical Significance.
10.19746/j.cnki.issn.1009-2137.2020.04.024
- Author:
Ya-Qi WU
1
;
Lu-Yao LUO
1
;
Ya-Nan TANG
1
;
Hu-Jun LI
1
;
Yan-Jie LI
1
;
Ying WANG
1
;
Yao YAO
1
;
De-Peng LI
1
;
Kai-Lin XU
1
;
Zhen-Yu LI
2
Author Information
1. Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.
2. Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China,E-mail: lizhenyumd@163.com.
- Publication Type:Journal Article
- MeSH:
Bone Marrow;
Humans;
Multiple Myeloma;
RNA, Messenger;
Versicans
- From:
Journal of Experimental Hematology
2020;28(4):1228-1233
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the expression and clinical significant of VCAN and its related molecules in patients with MM.
METHODS:Ficoll density gradient centrifugation method was used to speared the bone marrow mononuclear cell in 25 cases of MM before and after treatment, the relative mRNA expression of VCAN and their related molecules (FAK, FN, MK, and HAS) in bone marrow was detected by real-time quantitative PCR, and their protein expression was determined by Western bolt.
RESULTS:The expression of VCAN, FK and FN in the effective group after treatment was significantly lower than that before treatment (P＜0.05), however, the expression of MK and HAS showed no statistically significantly different before and after treatment (P＜0.05). The expression of VCAN of patients in non remission group was significantly higher than that in control group (P＜0.05). The expression of FAK and FN of patients in no remission group was significant increased as compared with the patients in newly diagnosed group (P＜0.05). The relative expression of VCAN mRNA in the patients at 3rd stage was significantly higher than those at the 1st stage (P＜0.05) and control group but showed no significant difference to the patients at 2nd stage (P＜0.05). The expression of VCAN and its related proteins (FAK, MK, FN) showed positively correlation in bone marrow mononuclear cells of MM patients (P＜0.05). The correlation between VCAN and HAS was not statistically significant (r=0.259，P＞0.05). Survival analysis showed that the relative expression of VCAN mRNA was associated with OS (P=0.049) and PFS (P=0.041) in MM patients.
CONCLUSION:VCAN and its related molecules are highly expressed in MM patients; VCAN may act as potential biomarker in the development of multiple myeloma.
